Related Experiment Video
Updated: Jun 2, 2025
Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
Published on: October 28, 2021
Scutellarein Inhibits Osteosarcoma Growth by Targeting the TLR4/TRAF6/NF-κB Pathway
Yingxu Shi1, Yu Tang2, Zhiwei Sun3
1Department of Trauma Orthopedics, Affiliated Hospital of Jining Medical University, Jining, Shandong, 272007, People's Republic of China.
Purpose:
Osteosarcoma (OS) is the most common malignant tumor associated with poor patient outcomes and a limited availability of therapeutic agents. Scutellarein (SCU) is a monomeric flavone bioactive compound with potent anti-cancer activity. However, the effects and mechanisms of SCU on the growth of OS remain unknown.
Methods:
The Cell Counting Kit-8, colony formation assay and 5-ethynyl-2'-deoxyuridine (EdU) incorporation assays were used to analyze cell proliferation ability in vitro. TLR4/TRAF6/NF-κB signaling transduction was investigated by RNA sequencing analysis, quantitative real-time polymerase chain reaction, Western blotting, NF-κB luciferase reporter assay, immunofluorescent staining, and immunoprecipitation. Molecular docking and cellular thermal shift assay were employed to confirm the binding interaction between SCU and TLR4. The effects of SCU and TLR4 overexpression on OS growth were analyzed using a xenograft tumor model and immunohistochemical staining.
Results:
SCU was found to significantly inhibit OS cell proliferation, and RNA sequencing analysis suggested that the NF-κB pathway is closely associated with this process. Further studies revealed that SCU inhibited the canonical NF-κB pathway through its binding with TLR4, which disrupted the interaction of TLR4 and TRAF6. Moreover, SCU also repressed NF-κB signal transduction by inhibiting TLR4 expression. Furthermore, SCU was revealed to suppress OS cell proliferation by targeting TLR4 in vitro and in vivo.
Conclusion:
SCU exhibited a dual impact by inhibiting TLR4 expression and disrupting TLR4-TRAF6 interaction, resulting in NF-κB inactivation, thereby blocking OS growth.
Insights
Scutellarein (SCU) inhibits osteosarcoma (OS) growth by targeting Toll-like receptor 4 (TLR4). This dual action inactivates the NF-κB pathway, offering a potential new therapy for this common cancer.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Osteosarcoma (OS) is a prevalent malignancy with poor prognosis and limited treatment options.
- Scutellarein (SCU), a flavone, demonstrates anti-cancer properties, but its role in OS is unexplored.
Purpose of the Study:
- To investigate the effects of Scutellarein (SCU) on osteosarcoma (OS) cell growth.
- To elucidate the underlying molecular mechanisms of SCU action in OS.
Main Methods:
- Cell proliferation assays (CCK-8, colony formation, EdU) were used in vitro.
- TLR4/TRAF6/NF-κB signaling was analyzed via RNA sequencing, qPCR, Western blotting, and reporter assays.
- In vivo studies utilized xenograft models, with molecular interactions confirmed by docking and thermal shift assays.
Main Results:
- SCU significantly inhibited OS cell proliferation in vitro and in vivo.
- SCU disrupted the TLR4/TRAF6 interaction and repressed TLR4 expression, leading to NF-κB pathway inactivation.
- SCU directly binds to TLR4, confirming it as a key molecular target.
Conclusions:
- Scutellarein (SCU) suppresses osteosarcoma growth through a dual mechanism involving TLR4 inhibition and TLR4-TRAF6 interaction disruption.
- This leads to NF-κB pathway inactivation, presenting SCU as a promising therapeutic agent for osteosarcoma.
Related Concept Videos
02:26NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
01:16TGF - β Signaling Pathway
01:12Role Of Notch Signalling In Intestinal Stem Cell Renewal
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...